135 related articles for article (PubMed ID: 32823413)
21. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
Glassman AR; Wells JA; Josic K; Maguire MG; Antoszyk AN; Baker C; Beaulieu WT; Elman MJ; Jampol LM; Sun JK
Ophthalmology; 2020 Sep; 127(9):1201-1210. PubMed ID: 32402554
[TBL] [Abstract][Full Text] [Related]
22. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
24. The area of fixation covaries with short-term changes in visual acuity after anti-vascular endothelial growth factor treatment in patients with diabetic macular oedema.
Jakobsen NS; Larsen DA; Bek T
Acta Ophthalmol; 2018 Nov; 96(7):744-748. PubMed ID: 29687595
[TBL] [Abstract][Full Text] [Related]
25. Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.
Savur F; Kaldırım H; Atalay K; Korkmaz Ş
Cutan Ocul Toxicol; 2021 Dec; 40(4):326-331. PubMed ID: 34275395
[TBL] [Abstract][Full Text] [Related]
26. PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA.
Shah SU; Harless A; Bleau L; Maturi RK
Retina; 2016 Oct; 36(10):1986-96. PubMed ID: 27124881
[TBL] [Abstract][Full Text] [Related]
27. Results of the first 12 months treatment of macular edema complicating BRVO in patients treated with ranibizumab.
Lalinská L; Krásný J; Studený P; Veith M
Cesk Slov Oftalmol; 2018; 74(2):62-67. PubMed ID: 30441951
[TBL] [Abstract][Full Text] [Related]
28. Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial.
Bressler SB; Odia I; Maguire MG; Dhoot DS; Glassman AR; Jampol LM; Marcus DM; Solomon SD; Sun JK;
JAMA Ophthalmol; 2019 Apr; 137(4):382-389. PubMed ID: 30676635
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study.
Chiquet C; Dupuy C; Bron AM; Aptel F; Straub M; Isaico R; Romanet JP; Creuzot-Garcher C
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2095-102. PubMed ID: 25673251
[TBL] [Abstract][Full Text] [Related]
30. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
31. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of micropulse laser combined with ranibizumab in diabetic macular edema treatment: study protocol for a randomized controlled trial.
Mi X; Gu X; Yu X
Trials; 2022 Sep; 23(1):736. PubMed ID: 36056443
[TBL] [Abstract][Full Text] [Related]
33. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
34. Epidemic Retinitis with Macular Edema -Treatment Outcome with and without Steroids.
Kawali A; Srinivasan S; Mohan A; Bavaharan B; Mahendradas P; Shetty B
Ocul Immunol Inflamm; 2021 Jul; 29(5):932-936. PubMed ID: 31961210
[No Abstract] [Full Text] [Related]
35. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
[TBL] [Abstract][Full Text] [Related]
37. Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study.
Shimura M; Kitano S; Muramatsu D; Fukushima H; Takamura Y; Matsumoto M; Kokado M; Kogo J; Sasaki M; Morizane Y; Kotake O; Koto T; Sonoda S; Hirano T; Ishikawa H; Mitamura Y; Okamoto F; Kinoshita T; Kimura K; Sugimoto M; Yamashiro K; Suzuki Y; Hikichi T; Washio N; Sato T; Ohkoshi K; Tsujinaka H; Kusuhara S; Kondo M; Takagi H; Murata T; Sakamoto T;
Br J Ophthalmol; 2020 Sep; 104(9):1209-1215. PubMed ID: 31784500
[TBL] [Abstract][Full Text] [Related]
38. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
39. Correlation of Response between Both Eyes to First- and Second-Line Anti-VEGF Therapy in Diabetic Macular Edema.
Tiosano L; Ayalon A; Banin E; Averbukh E; Jaouni T; Chowers I
Curr Eye Res; 2021 Apr; 46(4):539-545. PubMed ID: 32804540
[TBL] [Abstract][Full Text] [Related]
40. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E;
Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
